Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 6/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.38 |
| ▸ | PYGL | P06737 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1590690 | 0.93 | ACKR3 (0.43) | ACKR3MAPTCCR8P2RX7PARP1 | |
| SCHEMBL1591751 | 0.91 | ACKR3 (0.45) | ACKR3KDM4EALDH1A1CCR8P2RX7 | |
| SCHEMBL1590249 | 0.89 | ALDH1A1 (0.40) | KMT2AACKR3MAPTKDM4EALDH1A1 | |
| SCHEMBL1590333 | 0.89 | P2RX7 (0.40) | KDM4EALDH1A1P2RX7PYGL | |
| SCHEMBL1590675 | 0.87 | CCR8 (0.41) | ACKR3MAPTCCR8P2RX7PYGL | |
| SCHEMBL1591609 | 0.87 | NPC1 (0.47) | KMT2AACKR3MAPTALDH1A1CCR8 | |
| SCHEMBL1591507 | 0.85 | CCR8 (0.41) | KMT2AACKR3MAPTCCR8P2RX7 | |
| SCHEMBL1590939 | 0.85 | TAS1R3 (0.42) | MAPTCCR8P2RX7PYGLPARP1 | |
| SCHEMBL1590972 | 0.84 | CNR2 (0.46) | MAPTKDM4E | |
| SCHEMBL1590454 | 0.84 | TP53 (0.44) | KMT2AKDM4EP2RX7PYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. | 2011-04-21 | — | — | US | claimed |
| US-7816371-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | SECOND GENOME, INC. | 2007-09-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225324-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885ACKR3 136/4885MAPT 4477/4885 |
| US-20110092476-A1 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885ACKR3 136/4885MAPT 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.